Attendees who purchased access to the 2016 Annual Meeting webcast were sent login information on May 11, 2016.

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 7 records per page: next > | last >>
pages: 1 2 3 4 5 6 7 presentations: 1 to 25 of 164
p53-Dependent and -Independent Roles of Mdm2 in Cancer Cells and Human Disease
Invited Speaker
Carol L. Prives
Columbia University, New York, NY, United States
from AACR Annual Meeting 2016 on April 17, 2016 7:00 AM-8:00 AM
Glioma Reclassification and Evolution
Frequent driver gene mutations refine the classification of malignant adult gliomas
Hai Yan
Duke University Medical Center, Durham, NC, United States
from AACR Annual Meeting 2016 on April 18, 2016 1:00 PM-2:45 PM
Glioma Reclassification and Evolution
Targeting signal transduction pathways in glioma
Ingo K. Mellinghoff
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from AACR Annual Meeting 2016 on April 18, 2016 1:00 PM-2:45 PM
Early Clinical Trials of Novel Agents
Treatment for metastatic platinum-resistant urothelial cancer (PRUC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): phase I/II clinical experience
Scott T Tagawa
Weill Cornell Medicine, New York, NY, United States
from AACR Annual Meeting 2016 on April 18, 2016 3:00 PM-5:00 PM
Early Clinical Trials of Novel Agents
Labetuzumab govitecan (IMMU-130), an anti-CEACAM5/SN-38 antibody-drug conjugate, is active in patients (pts) with heavily pretreated metastatic colorectal cancer (mCRC): phase II results
Jordan D Berlin
Vanderbilt-Ingram Cancer Center, Nashville, TN, United States
from AACR Annual Meeting 2016 on April 18, 2016 3:00 PM-5:00 PM
Early Clinical Trials of Novel Agents
A randomized phase II, double-blind study to evaluate the efficacy and safety of galunisertib+gemcitabine (GG) or gemcitabine+placebo (GP) in patients with unresectable pancreatic cancer (PC)
Davide Melisi
University of Verona, Verona, Italy
from AACR Annual Meeting 2016 on April 18, 2016 3:00 PM-5:00 PM
Early Clinical Trials of Novel Agents
2-hydroxyoleic acid (2-OHOA), a novel activator of sphingomyelin synthase with antitumor activity in refractory glioblastoma: results of the first-in-human dose-escalation (DE) study in patients with advanced solid tumors (AST) and refractory gliomas/glioblastomas
Juanita S Lopez
Institute of Cancer Research, London, United Kingdom
from AACR Annual Meeting 2016 on April 18, 2016 3:00 PM-5:00 PM
Early Clinical Trials of Novel Agents
Discussant
Jeffrey R. Infante
Sarah Cannon Research Institute, Nashville, TN, United States
from AACR Annual Meeting 2016 on April 18, 2016 3:00 PM-5:00 PM
Early Clinical Trials of Novel Agents
First-in-human phase I trial of the oral PLK4 inhibitor CFI-400945 in patients with advanced solid tumors
Philippe L Bedard
Princess Margaret Cancer Centre, Toronto, ON, Canada
from AACR Annual Meeting 2016 on April 18, 2016 3:00 PM-5:00 PM
Early Clinical Trials of Novel Agents
Correlative biomarkers of clinical activity of the BCL-2 inhibitor, venetoclax (ABT-199/ GDC-0199), in acute myeloid leukemia patients
Brenda J. Chyla
AbbVie, Inc, North Chicago, IL, United States
from AACR Annual Meeting 2016 on April 18, 2016 3:00 PM-5:00 PM
Early Clinical Trials of Novel Agents
Biomarker and clinical response of oral cavity squamous cell carcinoma to the MEK 1/2 inhibitor trametinib: A phase II neoadjuvant window of opportunity clinical trial
Ravindra Uppaluri
Washington University, St. Louis, MO, United States
from AACR Annual Meeting 2016 on April 18, 2016 3:00 PM-5:00 PM
Early Clinical Trials of Novel Agents
Discussant
S Gail Eckhardt
University of Colorado Cancer Center, Aurora, CO, United States
from AACR Annual Meeting 2016 on April 18, 2016 3:00 PM-5:00 PM
Contribution of the Microenvironment to Therapy-Induced Resistance in Cancer
Tumor microenvironment instigates anti-viral signaling to regulate therapy resistance
Andy J Minn
Abramson Family Cancer Research Inst., Philadelphia, PA, United States
from AACR Annual Meeting 2016 on April 19, 2016 10:30 AM-12:15 PM
Contribution of the Microenvironment to Therapy-Induced Resistance in Cancer
Antiangiogenic therapy and immune modulation
Gabriele Bergers
UCSF, San Francisco, CA, United States
from AACR Annual Meeting 2016 on April 19, 2016 10:30 AM-12:15 PM
Contribution of the Microenvironment to Therapy-Induced Resistance in Cancer
Overcoming MAPK inhibitor resistance in melanoma
Meenhard Herlyn
The Wistar Institute, Philadelphia, PA, United States
from AACR Annual Meeting 2016 on April 19, 2016 10:30 AM-12:15 PM
Metabolic Rewiring in Cancer
Metabolic heterogeneity in human tumors in vivo
Ralph J. DeBerardinis
UT Southwestern Medical Center, Dallas, TX, United States
from AACR Annual Meeting 2016 on April 19, 2016 1:00 PM-2:45 PM
Metabolic Rewiring in Cancer
Metabolic vulnerabilities in cancer
Eyal Gottlieb
The Beatson Institute for Cancer Research, Glasgow, United Kingdom
from AACR Annual Meeting 2016 on April 19, 2016 1:00 PM-2:45 PM
Metabolic Rewiring in Cancer
Quantitative analysis of metabolic activity in cancer
Joshua D Rabinowitz
Princeton Univ., Princeton, NJ, United States
from AACR Annual Meeting 2016 on April 19, 2016 1:00 PM-2:45 PM
Population Genetics Meets Single Cell Analysis
Mapping tumor heterogeneity and ecosystem
Dana Pe'er
Columbia University, New York, NY, United States
from AACR Annual Meeting 2016 on April 19, 2016 1:00 PM-2:45 PM
Population Genetics Meets Single Cell Analysis
Accumulation of somatic mutations in normal and cancerous tissues with age
Margaret L Hoang
Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD, United States
from AACR Annual Meeting 2016 on April 19, 2016 1:00 PM-2:45 PM
Population Genetics Meets Single Cell Analysis
The clinical utility of single molecule mutation detection in mitochondrial and nuclear DNA
Jason H. Bielas
Fred Hutchison Cancer Research Center, Seattle, WA, United States
from AACR Annual Meeting 2016 on April 19, 2016 1:00 PM-2:45 PM
Population Genetics Meets Single Cell Analysis
Clonal evolution of glioblastoma under therapy
Raul Rabadan
Columbia Univ. Medical Ctr., New York, NY, United States
from AACR Annual Meeting 2016 on April 19, 2016 1:00 PM-2:45 PM
Pediatric Cancers and Epigenetic Therapies: Promise and Challenges
Emerging epigenetic targets in high-risk pediatric solid tumors
Kimberly Stegmaier
Dana-Farber Cancer Institute, Boston, MA, United States
from AACR Annual Meeting 2016 on April 20, 2016 9:45 AM-11:30 AM
Pediatric Cancers and Epigenetic Therapies: Promise and Challenges
Dissecting the role of histone mutations in high-grade pediatric brain tumors
Nada Jabado
McGill University Department of Pediatrics, Montreal, QC, Canada
from AACR Annual Meeting 2016 on April 20, 2016 9:45 AM-11:30 AM
Pediatric Cancers and Epigenetic Therapies: Promise and Challenges
Zebrafish models of PAX3-FOXO1 pathogenesis reveal novel targets in human rhabdomyosarcoma
Genevieve Kendall
UT Southwestern Medical Center, Dallas, TX, United States
from AACR Annual Meeting 2016 on April 20, 2016 9:45 AM-11:30 AM
<< first | < prev page: of 7 records per page: next > | last >>
pages: 1 2 3 4 5 6 7 presentations: 1 to 25 of 164